Pharmacy

Your Article Summary

See Latest Articles

Statins and cancer risk
American Journal of Medicine, 03/28/08

Karp I et al. - Use of lipophilic statins at sufficiently high dose might be associated with a clinically important reduction in the incidence of cancer.

• Objective was to investigate the relation between lipophilic statin use and cancer occurrence
• Pts (aged >=45 y) and survivors of acute myocardial infarction were included
• High- and low-dose statin use were defined as at or above (below) the statin-specific target dose, for any of the 4 lipophilic statin medications
• 30,076 pts, including high-dose, low dose, and non users were followed for up to 7 y

• Incidence rates of any type of cancer were 13.9, 17.2, and 26.0/1000 person-years in statin high-dose, low-dose, and non-users, respectively
• No significant time-dependence of the effect of statins at either dose was detected

Today in Chemotherapy/Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
British Journal of Haematology, 11/20/09

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
British Journal of Cancer, 11/20/09

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 11/20/09

 See all of Chemotherapy/Oncology